End-Stage Renal Disease
Conditions
Interventions
Experimental group: icodextrin peritoneal dialysis solution for nocturnal retention of abdominal dialysis
The control group:2.5% glucose peritoneal dialysis solution for nocturnal retention of abdominal dialysis
Sponsors
First Affiliated Hospital of Kunming Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1) Sign a written informed notice; 2) 18 years = 90 d (eluting phase); 4) Patients requiring 2-3 daytime fluid changes and 1 nighttime fluid change using 2.5% glucose peritoneal dialysis solution 2.0L with prolonged nighttime abdominal retention (8-10h) every 24h during the 30d prior to the screening visit; 5) Urine output <= 750 ml/d; 6) High transit or high mean transit as judged by peritoneal equilibrium test (PET).
Exclusion criteria
Exclusion criteria: 1) Failure to sign a written informed consent form or inability/unwillingness to comply with the investigator-approved study protocol; 2) Hypersensitivity to corn starch or icodextrin; 3) Patients with maltose or isomaltose intolerance and those with glycogen storage disease; 4) Serious illness or injury within 30d prior to the visit; 5) Acute or chronic peritoneal dialysis tubing outlet or tunnel infection at the time of the visit, or peritonitis requiring antibiotic therapy at the time of the visit or 30d prior to the visit; 6) Having other serious illnesses such as cirrhosis, heart failure, tumors, severe lactic acidosis, etc; 7) Pregnant or lactating women; 8) Being involved in other interventional studies or having participated in other interventional studies in the 3 months prior to enrollment; 9) Having used icodextrin peritoneal dialysis solution or other experimental drugs within 30d prior to the visit; 10) previous history of impairment of peritoneal function or extensive adhesions leading to reduced peritoneal function 11) Patients with a life expectancy of <12 months; 12) Patients whose condition is judged by the investigator to be unsuitable for participation in this pilot study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Volume status;Ultrafiltration volume; | — |
Secondary
| Measure | Time frame |
|---|---|
| Peritoneal solute transport rate;Adequacy of dialysis;Residual renal function;Blood pressure;Survival rate;Technology Survival Rate;Complications; | — |
Countries
China
Contacts
Public ContactZhou Zhu
First Affiliated Hospital of Kunming Medical University
Outcome results
None listed